PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):: US23283K2042 (+1 more)
LEI:
Country:: United States of America
Address:: 4200 MARATHON BLVD., 78756 AUSTIN
Website:: http://www.plustherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ILYANG PHARMACEUTICAL CO.,LTD Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.	South Korea	007570
I-Mab A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.	United States of America	IMAB
ImageneBio, Inc. A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.	United States of America	IMA
IM Cannabis Corp. International producer of medical-grade cannabis for patients and providers in Israel and Germany.	United States of America	IMCC
Immatics N.V. Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.	United States of America	IMTX
Immix Biopharma, Inc. Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.	United States of America	IMMX
IMMUCELL CORP /DE/ Develops biotech health products for disease prevention in dairy and beef cattle.	United States of America	ICCC
Immuneering Corp Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.	United States of America	IMRX
ImmuneOncia Therapeutics, Inc. A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.	South Korea	424870
ImmunityBio, Inc. Develops immunotherapies activating the immune system to fight cancer and infectious diseases.	United States of America	IBRX